Rebonuputemcel is under clinical development by DiscGenics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Rebonuputemcel’s likelihood of approval (LoA) and phase transition for Degenerative Disc Disease took place on 20 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rebonuputemcel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Rebonuputemcel is under development for the treatment of lumber, cervical, adjacent level and herniated degenerative disc disease. It is administered as percutaneous injection and intradiscal injection. The cell therapy is based on Discosphere technology which is allogeneic, human disc-derived stem cell technology.
DiscGenics operates as a biotechnology company that develops advanced spinal therapeutics. The company develops therapies to treat patients with intervertebral disc diseases. It provides products such as Injectable Discogenic Cell Therapy (IDCT), developed for treating patients with moderately degenerated discs; and Surgical Discogenic Cell Therapy (SDCT), developed for treating patients with herniated discs. DiscGenics develops adult human disc stem cells within tissue engineering to develop new approaches. It provides technology Discosphere which is a novel method used to efficiently isolate stem-like progenitor cells from human adult intervertebral disc tissues. DiscGenics is headquartered in Salt Lake City, Utah, the US.
Quick View Rebonuputemcel LOA Data
|Highest Development Stage|